Top-line data from the latest trial of ResApp’s smartphone-based diagnostic algorithm for respiratory diseases suggest that the machine learning tool’s conclusions generally align with clinical diagnoses when employed for younger patients.
The double-blind, prospective Breathe-Easy pediatric study was conducted among a cohort of 585 Australian children whose ages ranged from 29 days to 12 years,...
Stockholm, Sweden-based respiratory monitor maker NuvoAir (formerly Pond Healthcare Innovation) has unveiled the newest version of its home-use spirometer.
Dubbed the Air Next, the small and portable device is connected to users’ smartphones or tablets via Bluetooth LE. In contrast, the company’s previous offering, the Air Smart Spirometer, required a hard connection through a device’s audio jack...
Brisbane, Australia-based ResApp intended to have its software, which uses a smartphone microphone to diagnose respiratory conditions based on coughs, well on its way through the FDA by now. But this past summer, the company’s big plans hit a major setback when the data came back from its landmark clinical trial, conducted at such austere institutions as Massachusetts General Hospital, Cleveland...
Adherium, a Melbourne, Australia-based connected inhaler company, has raised $5.9 million ($8 million Australian) through a private placement of shares with Fidelity. Adherium is publicly traded in Australia. Under the deal, Fidelity will purchase 16 million shares at $0.50 Australian per share, bringing the global asset manager's share in the company to 10 percent.
“Fidelity International are...
Propeller Health has announced yet another collaboration with a pharmaceutical company. The Madison, Wisconsin-based company will parter with the Chippenham, UK-based Vectura Group, an independent pharma company focused exclusively on inhaler drugs for respiratory conditions.
“Digital health has the potential to make respiratory therapies more personal, powerful and convenient for every patient...
